ClinicalTrials.gg
Active, not recruitingNCT05540223BIOMAG-IIUpdated Jul 7, 2026

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System

An interventional study of Freesolve RMS and Xience DES in Coronary Artery Disease, Atherosclerosis, Coronary and Myocardial Ischemia, sponsored by Biotronik AG. Active, not recruiting at 1 site in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Biotronik AG (formerly part of Biotronik SE & Co. KG) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,861
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Coronary Artery Disease by Biotronik SE & Co. KG — 1 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · Biotronik SE & Co. KG.

Enrollment
2nd of 17
1,861 · median 202
Started
2024
the only one that year
No phase
15 of 37
none open now
Registered
37th of 37
by date

Among the 37 studies in Coronary Artery Disease by Biotronik SE & Co. KG, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2024, is one of 15 with no phase, and was the 37th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 37 studies in Coronary Artery Disease by Biotronik SE & Co. KG is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Coronary Artery Disease by Biotronik SE & Co. KG, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety and efficacy of the Freesolve in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to a contemporary drug eluting stent (DES).

Read the detailed description

The Biotronik BIOMAG-II clinical trial is a prospective, international, multi-center, randomized controlled, non-inferiority trial to compare the BIOTRONIK Sirolimus Eluting Resorbable Magnesium Scaffold System (Freesolve RMS) with the Xience Everolimus Eluting Stent System (Xience DES) with respect to Target Lesion Failure (TLF) rate at 12 months. A total of 1859 subjects will be enrolled at approximately 100 study sites Europe and APAC. Subjects will be randomized in a 2:1 ratio to Freesolve or Xience.

Clinical follow-up visits will take place at 1, 6, 12 and at 2-, 3-, 4- and 5-years post procedure.

03

Conditions studied

  • Coronary Artery Disease
  • Atherosclerosis, Coronary
  • Myocardial Ischemia
  • Ischemic Heart Disease
  • Acute Coronary Syndrome
  • Angina Pectoris

Keywords

  • Resorbable Magnesium Scaffold
  • Sirolimus
  • RMS
  • Drug eluting absorbable metal scaffold
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Clinical Inclusion Criteria:

  1. Subject is ≥ 18 years and ≤ 80 years of age
  2. Subject has provided written as approved by the Independent Ethical Committee (IEC) or Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures
  3. Subject is eligible for PCI according to the applicable guidelines
  4. Subject is an acceptable candidate for coronary artery bypass surgery
  5. Subjects with stable or unstable angina pectoris, documented silent ischemia/abnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion

    Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:

    • Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) [lesion(s) causing the acute STEMI];
    • Subject is hemodynamically stable with documented declining cardiac biomarkers;
    • Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)
  6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor or ticlopidine
  7. Documented (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to randomization)
  8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study

Angiographic Inclusion Criteria:

  1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries
  2. Target vessel must have a reference diameter between 2.5-4.2 mm by visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) / Intravascular Ultrasound (IVUS) / Optical Coherence Tomography (OCT)
  3. Target lesion must be ≤28mm in length by operator visual estimation, which may be assissted by QCA / IVUS / OCT, (or \< 20 mm for target lesion(s) to be treated with a study device \< 3.0 mm in diameter) and should be amenable to treatment with a single study device
  4. Target lesion stenosis ≥ 50% and \< 100% by operator visual estimation, which may be assisted by QCA / IVUS / OCT. Target lesion stenosis \< 70% by visual estimation, should have clinical justification for treatment as per local standards.
  5. Target lesion must have a Thrombolysis In Myocardial Infarction (TIMI) flow ≥1

Clinical Exclusion Criteria:

  1. Subject is pregnant and/or breastfeeding or intends to become pregnant during the duration of the study
  2. Subject has clinical symptoms and/or (ECG) changes consistent with STEMI \< 72 hours prior to the index procedure.

    Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment.

  3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \<72 hours prior to the index procedure if successful and uncomplicated
  4. Subject is on dialysis or with impaired renal function (serum creatinine > 2.5 mg/dL or 221 µmol/L, determined within 72 hours prior to the index procedure)
  5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus, everolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminium, tantalum), or Xience stent material (cobalt, chromium, tungsten, nickel, -methacrylic polymer, and fluoropolymer)
  6. Subject is receiving oral or intravenous therapy (inhaled are permitted) or has known life-limiting immunosuppressive or disease (e.g., , systemic lupus erythematosus; diabetes mellitus is permitted)
  7. less than 1 year
  8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained
  9. In the investigator's opinion subject will not be able to comply with the follow-up requirements
  10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e. triple therapy) can be maintained for a minimum of 1 month
  11. Subject has had a stroke or (TIA) within 6 months prior to the index procedure
  12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT
  13. Subject is currently participating or plans to participate in another study with an device or an investigational drug

Angiographic Exclusion Criteria:

  1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion
  2. Left main coronary artery disease
  3. Target lesion was totally occluded (100% stenosis)
  4. Thrombus in target vessel
  5. Future planned staged PCI either in target or non-target vessel
  6. Ostial target lesion within the left descending (LAD), left circumflex (LCx), or right coronary artery (within 5.0 mm of vessel origin)
  7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation
  8. Target lesion is located in or supplied by an arterial or venous bypass graft
  9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and/or cutting/scoring balloon as described in angiographic exclusion criteria 10.
  10. The target lesion requires treatment with the device other than the non-compliant balloon and/or cutting/scoring balloon prior to scaffold/stent placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons etc.)
  11. Target vessel was treated with brachytherapy any time prior to the index procedure.
  12. Unsuccessful pre-dilatation, defined as residual stenosis > 20% (by visual estimation) and / or angiographic complications (e.g. distal embolization, side branch closure, flow-limiting dissections)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,861 participants (actual)

Study arms

  • Experimental
    Freesolve RMS

    Intervention with a Freesolve Sirolimus Eluting Resorbable Coronary Magnesium Scaffold System

    Device: Freesolve RMS

  • Active comparator
    Xience DES

    Intervention with a Xience Everolimus Eluting Stent System

    Device: Xience DES

Interventions

  • DeviceFreesolve RMS

    Subject undergoes implantation of Freesolve RMS

    Also known as: DREAMS 3G Sirolimus Eluting Resorbable Coronary Magnesium Scaffold System

  • DeviceXience DES

    Subject undergoes implantation of Xience DES

    Also known as: Xience Everolimus Eluting Stent System

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Target Lesion Failure (TLF) at 12 Months Post-Index Procedure

    The primary endpoint will be Target Lesion Failure (TLF) at 12 months. TLF is a composite of Cardiac Death, Target Vessel Q-wave or non-Q wave MI, or clinically driven Target Lesion Revascularization (TLR).

    Time frame: 12 Months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — An IPD plan is being developed.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Feb 2027, 33 months after the start.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 33 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2022
First posted
Sep 14, 2022
StartActual
May 13, 2024
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2032
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05540223
Lead sponsor
Biotronik AG
Responsible party
Sponsor
First posted
Sep 14, 2022
Start date
May 13, 2024
Primary completion
Feb 2027 (estimated)
Completion
Feb 2032 (estimated)
Last update
Jul 7, 2026

Study contacts

Michael Haude, MD
principal investigator · Rheinland Klinikum Neuss GmbH Lukaskrankenhaus Neuss

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion